Sandip Prasad, MD, MPhil, of Garden State Urology, Atlantic Health System, provides an overview of the differences between ATLAS and ENVISION, shares the treatment-related adverse events associated with UGN-102 in both studies, and opines on whether the data are strong enough to make UGN-102 a practice-changing alternative to TURBT for intermediate-risk, low-grade non-muscle invasive bladder cancer (NMIBC).
Do the results of ATLAS suggest that UGN-102 is a superior therapeutic alternative to TURBT for intermediate-risk, low-grade NMIBC? Dr. Prasad suggests that this is the “hallmark question” and points to the reported tumor-free complete response after 3 months of treatment as well as the estimated probability of disease-free survival after 15 months to make his case.
Further updates are expected from the ENVISION trial in 2024. Reported topline data suggest that patients treated with UGN-102 had a 79.2% rate of complete response after 3 months of treatment.